Stephen Ubl, president and chief executive officer of PhRMA (Photographer: Andrew Harrer/Bloomberg via Getty Images)
July 27, 2022 02:42 PM EDT
Pharma

Two sides of 'his­toric' drug pric­ing bill: Phar­ma in­dus­try blasts 'mis­take' while ad­vo­cates plan for 'first ever' gains

Beth Snyder Bulik

Senior Editor

Both Con­gres­sion­al De­moc­rats and the phar­ma in­dus­try agree that pend­ing drug pric­ing leg­is­la­tion is “his­toric” — they just di­a­met­ri­cal­ly dis­agree on the mod­i­fi­er.

Trade in­dus­try group …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times